Combination anti-Aß treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice

Keyphrases

• Mammalian Target of Rapamycin (mTOR) 100%
• Anti-A 100%
• APP Mice 100%
• Cognitive Recovery 100%
• Rebalance 100%
• Alzheimer's Disease 50%
• Mouse Model 50%
• Transgenic Mouse Model 50%
• Cell Behavior 50%
• Drug Development 50%
• Functional Outcome 50%
• Immunization 50%
• Passive Immunization 50%
• Combination Treatment 50%
• Cognitive Function 50%
• Mammalian Target of Rapamycin Signaling 50%
• Computational Modeling 50%
• APP Transgenic Mice 50%
• Microdialysis 50%
• Single Treatment 50%
• Working Memory 50%
• Postsynaptic Density Protein 95 (PSD-95) 50%
• Genetic Suppression 50%
• Spatial Learning 50%
• Neuritic Dystrophy 50%
• Cognitive Improvement 50%
• Associative Memory 50%

Neuroscience

• Blood Group A Antibody 100%
• mTOR Signaling 100%
• Alzheimer's Disease 50%
• In Vivo 50%
• Behavior (Neuroscience) 50%
• Cognitive Function 50%
• Mammalian Target of Rapamycin 50%
• Amyloid Protein 50%
• Gene Repression 50%
• Associative Memory 50%
• Microdialysis 50%
• Working Memory 50%

Biochemistry, Genetics and Molecular Biology

• Mouse Model 100%
• mTOR Signaling 100%
• Transgenic Mouse 50%
• Mechanistic Target of Rapamycin 50%
• Microdialysis 50%
• Gene Repression 50%
• Working Memory 50%
• Spatial Learning 50%
• Associative Memory 50%
• Amyloid Protein 50%